£122.9m market cap
105p last close
Shield Therapeutics is a commercial-stage pharmaceutical company. Its proprietary product, Feraccru, is approved by the EMA for iron deficiency and is undergoing review with the US FDA. Feraccru is currently marketed through partners Norgine, AOP Orphan and Ewopharma.
Investment summary
Shield Therapeutics is a commercial-stage speciality pharmaceutical company based in the UK. Its primary focus is the commercialisation of Feraccru, approved by the EMA for the treatment of iron deficiency, with or without anaemia. Commercialisation of Feraccru in key markets (ex US) is in the hands of distribution partners Norgine, AOP Orphan and Ewopharma. Top-line data from a Phase IIIb marketing study (AEGIS-H2H) announced in March were positive, and should drive clinical uptake and aid top-line growth. Shield retains the marketing rights to the US market and will seek a partner once a decision on regulatory approval is reached by the US FDA (PDUFA date 27 July 2019).
Y/E Dec |
Revenue (£m) |
EBITDA (£m) |
PBT (£m) |
EPS (p) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 0.6 | (18.5) | (18.4) | (17.4) | N/A | N/A |
| 2018A | 11.9 | (2.8) | (5.2) | (2.0) | N/A | N/A |
| 2019E | 3.0 | (7.0) | (9.4) | (6.5) | N/A | N/A |
| 2020E | 2.7 | (7.9) | (10.2) | (7.8) | N/A | N/A |
| Last updated on 17/05/2019 | ||||||
Industry outlook
The market for iron deficiency is substantial, and Feraccru is a unique oral formulation of iron developed to overcome the side effect profile of salt-based oral iron therapies, and provides an alternative treatment to intravenously (IV) administered iron.
Last updated on 17/05/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (£m) | 4.7 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Carl Sterritt | CEO |
| Tim Watts | Interim CFO |
